Lymphoma Coalition 2020 Global Patient Survey - Week 6 Update

Dear Members,

To date, we have received 7352 responses (patient and caregiver surveys combined) to the 2020 Global Patient Survey on Lymphomas & CLL. Thanks to everyone's hard work, we have almost reached our goal of 7500 responses!

Even though we are close to goal, please continue to promote the survey. Every voice is important in ensuring the results learned from the survey are representative of patient and carer experience globally. Promoting the survey works and we encourage each group to participate. Keep reading to the end of this email for more information on marketing the survey, including information on what has been translated for your use.

See below for the survey count by member countries for patient respondents. Please remember caregivers have their own survey this year and these numbers are being tracked separately.  

Algeria 3 Latvia 0
Argentina 69 Lithuania 29
Australia 190 Macedonia 0
Barbados 1 Mexico 7
Belgium 115 Morocco 11
Brazil 6 New Zealand 286
Bulgaria 64 Norway 4
Canada 359 Poland 0
China 838 Portugal 16
Colombia 1 Romania 1
Croatia 10 Russia 0
Czech Republic 2 Serbia 105
Denmark 12 Singapore 0
Finland 39 Slovakia 48
France 1206 Slovenia 11
Germany 37 South Africa 4
Greece 4 Spain 31
Hong Kong 10 Sweden 163
Hungary 2 Switzerland 46
India 78 The Netherlands 239
Iraq 0 Turkey 1
Ireland 105 Ukraine 0
Israel 2 United Kingdom 466
Italy 432 United States 571
Japan 38 Uruguay 26
Korea 67 Venezuela 1

The highlighted countries have surpassed 100 respondents, and will receive a country report. 

Congratulations to Serbia for reaching over 100 respondents, and for China who saw a massive increase in numbers this past week. A few more countries are getting close – keep up the good work everyone!

We have also tracked the survey completion counts by subtype from patient respondents:

Anaplastic large cell 48
Burkitts 62
CL 307
CLL/SLL 1404
DLBCL (unspecified) 564
Extranodal Killer T-cell 52
FL 879
HL 786
MALT 132
Mantle cell 155
Peripheral T-cell 64
Transformed 86
WM 591

The highlighted subtypes have surpassed 100 respondents, and will have a subtype report. ​ 

Thank you to everyone who has already shared the 2020 Global Patient Survey. For those that have not done so, please share the link with your membership, healthcare community and social media. The marketing materials can be found on the members side of the LC website. The materials have all been translated into the same 19 languages that the survey is offered in. CLICK HERE to access them. Your login is required. If you need help with your username and password, please contact

Here's what you can do to help us reach our goal:

  • Host the information on your website. 
  • Send an email to your membership, sponsors and other partners encouraging them to take the survey and pass the message along.
  • Share with your followers on social media.
  • Here is the link to the survey from the LC website
  • Here is the link directly to the survey (if you share this link, the survey will automatically show in the language that the respondent’s internet browser uses if it is one of the translated languages).

Reminder – countries with 100+ respondents (from patients) will receive a specialised by country report. 

All your efforts to help promote participation in the 2020 Global Patient Survey are greatly appreciated.

The survey will be open for just over two more weeks and will officially close on 11 March 2020.

Together, we will ensure patients are given the opportunity to share their experience and help shape the global lymphoma landscape.
Warm regards,



Zagreb, HR
umjerena kiša

Hrvatska udruga leukemija i limfomi
predsjednik Dražen Vincek
Trg hrvatskih velikana 2/ll
10 000 Zagreb
GSM: +385 (0)91 4873 561
TEL: +385 (0)1 4873 561
Web adresa:
IBAN: HR 36 2340 0091 1100 4711 4

Važni datumi


Health through Knowledge

Klasa optimist

Istaknuti sponzori HULL-a